Read More Biotech Events FDA General News NextCure Presents Initial Data From Clinical Trial Of NC762 And A Trial In Progress Poster For NC410 Combo At The 2022 Society For Immunotherapy Of Cancer Annual Meeting By Benzinga Newsdesk November 7, 9:12 AM NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today NXTC
Read More Equities Movers News Top Stories Trading Ideas Why Rivian Stock Is Cratering Premarket Today By Shanthi Rexaline October 5, 5:54 AM Rivian said late Wednesday it plans to offering $1.5 billion worth of debt and also pre-announced Q3 revenue that surrounded the consensus. RIVN
Read More Analyst Ratings News Price Target JP Morgan Maintains Neutral on Hamilton Lane, Lowers Price Target to $85 By Benzinga Newsdesk February 8, 9:31 AM JP Morgan analyst Ken Worthington maintains Hamilton Lane (NASDAQ:HLNE) with a Neutral and lowers the price target from $86 to $85. HLNE
Read More Analyst Ratings Downgrades News Price Target Wells Fargo Downgrades Cardlytics to Underweight, Lowers Price Target to $13 By Benzinga Newsdesk September 8, 6:08 AM Wells Fargo analyst Jeff Cantwell downgrades Cardlytics (NASDAQ:CDLX) from Equal-Weight to Underweight and lowers the price target from $14 to $13. CDLX